Eton Pharmaceuticals Inc (OQ:ETON)

Business Focus: Specialty & Advanced Pharmaceuticals

Mar 22, 2024 02:00 am ET
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. rights to PKU GOLIKE® from...
Mar 14, 2024 04:01 pm ET
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter and year ended...
Feb 29, 2024 04:01 pm ET
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023...
Feb 21, 2024 06:50 am ET
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (“USPTO”)...
Feb 02, 2024 06:50 am ET
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the...
Nov 09, 2023 04:01 pm ET
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30,...
Oct 30, 2023 06:50 am ET
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report...
Oct 18, 2023 08:00 am ET
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
DALLAS, Oct. 18, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. 
Oct 04, 2023 06:50 am ET
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced it...
Aug 23, 2023 06:50 am ET
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, will present at the H.C....
Aug 10, 2023 04:01 pm ET
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023....
Aug 01, 2023 04:05 pm ET
Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2023 financial results on Thursday, August...
Jul 19, 2023 02:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (NASDAQ: ETON).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Jul 17, 2023 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ: ETON).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jul 17, 2023 04:05 pm ET
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
DALLAS, July 17, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. 
Jul 12, 2023 01:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
NEW YORK , July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ: ETON). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 09, 2023 01:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (NASDAQ: ETON).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Jul 03, 2023 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
NEW YORK , July 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ: ETON). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 02, 2023 01:07 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (NASDAQ: ETON).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Jun 28, 2023 09:31 am ET
Thinking about buying stock in Applied Digital, Workhorse Group, Marathon Digital Holdings, Viking Therapeutics, or Eton Pharmaceuticals?
NEW YORK, June 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLD, WKHS, MARA, VKTX, and ETON.
Jun 28, 2023 06:50 am ET
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response...
May 11, 2023 04:01 pm ET
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2023....
May 10, 2023 06:50 am ET
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the commercial availability of Betaine Anhydrous for Oral Solution 180 grams for...
May 03, 2023 04:05 pm ET
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2023 financial results on Thursday, May 11,...
Mar 16, 2023 04:01 pm ET
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31,...
Mar 15, 2023 06:50 am ET
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600...
Mar 07, 2023 04:05 pm ET
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March 16,...
Jan 31, 2023 07:00 am ET
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
Fourth Quarter and Full Year 2022 Financial Results to be Announced in March
Jan 11, 2023 06:50 am ET
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has...
Nov 10, 2022 04:05 pm ET
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30,...
Nov 02, 2022 04:05 pm ET
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November...
Oct 18, 2022 04:05 pm ET
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
Third Quarter 2022 Financial Results to be Announced in Early November
Oct 18, 2022 06:50 am ET
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present...
Sep 27, 2022 09:05 am ET
60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago
RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor audience.
Sep 13, 2022 09:00 am ET
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of betaine anhydrous for oral solution. "We...
Aug 30, 2022 04:05 pm ET
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present...
Aug 11, 2022 04:01 pm ET
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2022. “The second quarter...
Aug 02, 2022 08:00 am ET
Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on Thursday, August...
Jul 18, 2022 07:05 am ET
Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONISADE™...
Jun 24, 2022 09:31 am ET
Thinking about buying stock in Li Auto, Genius Brands, Kanzhun, Eton Pharmaceuticals, or Xpeng?
NEW YORK, June 24, 2022 /PRNewswire/ --InvestorsObserver issues critical PriceWatch Alerts for LI, GNUS, BZ, ETON, and XPEV.
Jun 24, 2022 07:30 am ET
Eton Pharmaceuticals Announces Sale of Hospital Products
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has sold its hospital products to Dr. Reddy’s Laboratories SA, a...
May 12, 2022 04:02 pm ET
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022. “We are proud...
May 03, 2022 04:02 pm ET
Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12,...
Apr 11, 2022 04:01 pm ET
Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective...
Apr 11, 2022 08:30 am ET
Thinking about buying stock in Sailpoint Technologies, Veru, Eton Pharmaceuticals, AIM ImmunoTech, or Affimed?
NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAIL, VERU, ETON, AIM, and AFMD.
Apr 11, 2022 07:30 am ET
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration...
Mar 16, 2022 04:02 pm ET
Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter ended December 31, 2021. “Our business...
Mar 14, 2022 07:00 am ET
Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection. Rezipres (4.7 mg/mL) is a ready-to-use1 formulation of injectable ephedrine...
Mar 08, 2022 08:00 am ET
Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on Wednesday, March 16,...
Dec 20, 2021 07:30 am ET
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need...
Nov 18, 2021 02:04 pm ET
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the...
Nov 15, 2021 04:05 pm ET
Eton Pharmaceuticals Reports Third Quarter Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2021. “Over the last...
Nov 15, 2021 06:30 am ET
Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®. Eton will leverage Tolmar’s 62-person sales force and their existing...
Nov 08, 2021 06:00 am ET
Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution
Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EPRONTIA™ (topiramate) oral solution, 25mg/mL. EPRONTIA™ has been approved as a monotherapy...
Nov 03, 2021 04:15 pm ET
Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating results on Monday,...
Oct 28, 2021 07:30 am ET
Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. marketing rights to carglumic acid tablets. The...
Aug 16, 2021 04:02 pm ET
Eton Pharmaceuticals Reports Second Quarter Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021. “During the second...
Aug 03, 2021 04:05 pm ET
Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on...
Jun 15, 2021 04:05 pm ET
Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector
Eton Pharmaceuticals, Inc (Nasdaq: ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone...
Jun 15, 2021 10:37 am ET
Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of...
May 28, 2021 08:05 am ET
Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection
Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for dehydrated...
May 13, 2021 04:05 pm ET
Eton Pharmaceuticals Reports Record Revenue and Earnings
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an...
May 04, 2021 04:05 pm ET
Eton Pharmaceuticals to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2021 financial and operating results on...
Mar 17, 2021 04:05 pm ET
Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17,...
Mar 16, 2021 04:02 pm ET
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and...
Mar 04, 2021 04:05 pm ET
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16, 2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report fourth quarter and full year 2020...
Feb 16, 2021 04:05 pm ET
Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th...
Feb 08, 2021 08:00 am ET
Eton Pharmaceuticals Announces Sale of Neurology Portfolio
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity...
Jan 14, 2021 08:00 am ET
Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE...
Dec 17, 2020 08:00 am ET
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for...
Nov 24, 2020 09:00 am ET
Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the full availability of ALKINDI® SPRINKLE for sale and...
Nov 12, 2020 04:05 pm ET
Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ended September 30,...
Nov 04, 2020 04:05 pm ET
Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and operating...
Oct 16, 2020 04:05 pm ET
Eton Pharmaceuticals Announces Closing of Public Offering
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000...
Oct 15, 2020 08:30 am ET
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for...
Oct 14, 2020 08:30 am ET
Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000...
Oct 13, 2020 04:01 pm ET
Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an...
Oct 08, 2020 08:00 am ET
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for...
Oct 06, 2020 04:05 pm ET
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that in tandem with its development and manufacturing partner...
Sep 29, 2020 06:49 pm ET
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Sep 25, 2020 08:00 am ET
FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%
LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander, which is one of the
Sep 16, 2020 09:00 am ET
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner has not yet received a communication from the U.S. Food and Drug...
Aug 31, 2020 08:00 am ET
Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Ingrid Hoos as the company’s new Senior Vice President of...
Aug 12, 2020 08:30 am ET
Eton Pharmaceuticals Announces Second Quarter 2020 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the second quarter ended June 30, 2020 and provided an update on...
Aug 11, 2020 09:00 am ET
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner has not yet received a communication from the U.S. Food and Drug...
Aug 04, 2020 04:10 pm ET
Eton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday,...
Jul 30, 2020 08:00 am ET
Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has submitted a new drug application (NDA) for zonisamide oral suspension,...
Jul 27, 2020 07:30 am ET
Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has submitted a new drug application (NDA) for dehydrated alcohol injection,...
May 14, 2020 04:02 pm ET
Eton Pharmaceuticals Announces First Quarter 2020 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an update on...
May 07, 2020 08:00 am ET
Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today disclosed that it has been confirmed as the first filer of an Abbreviated New Drug Application...
May 06, 2020 04:30 pm ET
Eton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May...
May 04, 2020 08:00 am ET
Eton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice President of Sales...
Mar 27, 2020 07:00 am ET
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has acquired U.S. marketing rights to Alkindi® Sprinkle from Diurnal Group plc...
Mar 17, 2020 08:00 am ET
Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced positive bioequivalence study results for ET-101, its proprietary oral solution...
Mar 05, 2020 04:02 pm ET
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the fourth quarter ended December 31, 2019 and provided an update...
Feb 27, 2020 04:10 pm ET
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report fourth quarter and full year 2019 financial and operating results...
Feb 19, 2020 08:00 am ET
Eton Pharmaceuticals Provides Update on ET-105 Program
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET-105 product candidate, which is currently under review with the U.S....
Feb 13, 2020 04:05 pm ET
Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB...
Jan 21, 2020 07:00 am ET
Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion...
Dec 02, 2019 07:30 am ET
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Biorphen®, the first and only FDA-approved ready-to-use formulation of...
Nov 14, 2019 04:01 pm ET
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the third quarter ended September 30, 2019 and provided an update...
Nov 13, 2019 04:55 pm ET
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation. “We are...
Nov 06, 2019 04:05 pm ET
Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday,...
Oct 22, 2019 07:00 am ET
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S. Food and Drug Administration (FDA) has approved Biorphen®, the first and...
Sep 03, 2019 04:01 pm ET
Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in the Lake Street 3rd...
Aug 19, 2019 07:00 am ET
Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products today announced positive results from bioequivalence studies of ET-104, Eton’s proprietary oral liquid formulation of a molecule frequently used to treat a severe neurological condition.
Aug 06, 2019 04:01 pm ET
Eton Announces Second Quarter Financial Results and Highlights Business Progress
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the second quarter ended June 30, 2019 and provided an update on...
Aug 02, 2019 07:30 am ET
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian™ anti-microbial molecule for ophthalmic and otic...
Aug 01, 2019 08:01 am ET
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Aucta Pharmaceuticals' New Drug Application for ET-105, an innovative formulation...
Jul 30, 2019 08:01 am ET
Eton Pharmaceuticals to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2019 financial and operating results on Tuesday,...
Jul 25, 2019 07:30 am ET
Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30...
Jul 12, 2019 04:01 pm ET
Eton Pharmaceuticals Provides Update on EM-100 Program
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S Food and Drug Administration (FDA) provided Eton’s partner with a Complete...
Jun 13, 2019 04:01 pm ET
Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the Company has entered into an agreement with Aucta Pharmaceuticals, Inc to...
May 15, 2019 04:01 pm ET
Eton Pharmaceuticals to Present at 20th Annual B. Riley FBR Investor Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 20th Annual B....
May 07, 2019 04:05 pm ET
Eton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
DEER PARK, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the first quarter...
Apr 30, 2019 04:30 pm ET
Eton Pharmaceuticals to Report First Quarter 2019 Financial Results on Tuesday, May 7, 2019
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2019 financial and operating results on Tuesday, May...
Mar 25, 2019 08:01 am ET
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a...
Mar 14, 2019 08:00 am ET
Eton Pharmaceuticals Submits New Drug Application for DS-200
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previously granted Fast...
Feb 21, 2019 08:00 am ET
Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in a fireside chat at...
Feb 19, 2019 06:00 am ET
Feb 19, 2019 06:00 am ET
Feb 11, 2019 08:01 am ET
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into an exclusive licensing and supply agreement with Sintetica...
Jan 24, 2019 04:10 pm ET
Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a licensing and supply agreement for ET-104, an innovative...
Dec 20, 2018 06:30 am ET
Eton Pharmaceuticals Reports Third Quarter Results and Business Update
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the third quarter ended September 30, 2018 and provided a business...
Nov 16, 2018 07:30 am ET
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced that it ranked 88th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North...
Nov 12, 2018 04:52 pm ET
Eton Pharmaceuticals Announces Pricing of Initial Public Offering
Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at a...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.